<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164513</url>
  </required_header>
  <id_info>
    <org_study_id>116855</org_study_id>
    <nct_id>NCT02164513</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol
      (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with
      dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the
      use of an 'open' triple therapy (use of Inhaled Corticosteroid [ICS]/ Long-acting Muscarinic
      Receptor Antagonists [LAMA])/ Long Acting Beta-Agonist [LABA] delivered via multiple
      inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health
      Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to
      dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile
      with dual or monotherapy doses for periods of up to one year. Given the clinical experience
      with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from
      their known pharmacology, the potential benefit of a new therapy option in patients with
      moderate to severe COPD supports the further development of the closed triple combination
      (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion
      criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety
      follow-up period. Eligible subjects will be randomized to one of the following double-blind
      treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100
      mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2014</start_date>
  <completion_date type="Actual">July 17, 2017</completion_date>
  <primary_completion_date type="Actual">July 17, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The annual rate of moderate or severe COPD exacerbations which occurred during treatment was assessed. Moderate exacerbations were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Analysis performed using a generalized linear model assuming a negative binomial distribution. ITT population was used which comprised of all randomized participants, excluding those who were randomized in error. Only those participants with non-missing co-variates were included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>FEV1 was defined as the amount of air a person exhales in one second. Change from Baseline was calculated as the value of FEV1 at Week 52 minus the value at Baseline. Baseline for trough FEV1 was defined as Day 1 (Pre-dose). Only those participants with non-missing co-variates were included in the analysis. The analysis was performed using a Repeated measures model with covariates of treatment group, smoking status (Screening), geographical region, visit, Baseline, Baseline by visit and treatment group by visit interactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>SGRQ is a disease specific-questionnaire, designed to measure impact of respiratory disease and its treatment on a COPD participant's Health Related Quality of Life (HRQoL). SGRQ contains 14 questions with total of 40 items grouped into three domains (Symptoms, Activity, and Impacts). The overall summary score along with scores for the individual domains of symptoms, activity and impacts were assessed. Score was calculated by summing the pre-assigned weights of answers, dividing by sum of maximum weights for items in SGRQ. Total scores ranged from 0 to 100. A decrease in score indicates improvement in HRQoL and higher score implies worse quality of life. Change from Baseline was calculated as total score at Week 52 minus value at Baseline. Baseline was defined as Day 1. Minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Only those participants with non-missing co-variates were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This measures the number of days, to the first onset of moderate or severe exacerbations. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. The Hazard ratio from Cox proportional hazards model with covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening), have been reported. Only those participants with non-missing co-variates were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count &gt;=150 Cells Per Microliter</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The annual rate of moderate or severe COPD exacerbations during the treatment, for participants with blood eosinophil count &gt;=150 cells per microliter , has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non-missing eosinophil, at Baseline were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count &gt;=150 Cells Per Microliter at Baseline</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>This measures the number of days, to the first onset of moderate or severe exacerbations for participants with blood eosinophil count &gt;=150 cells per microliter, at Baseline has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non missing eosinophils at Baseline were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>The annual rate of severe COPD exacerbations during the treatment, has been reported. Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. The covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening) were used. Only those participants with non-missing co-variates were included in the analysis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10355</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>fluticasone furoate/umeclidinium bromide/vilanterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluticasone furoate/vilanterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>umeclidinium bromide/vilanterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone furoate (FF)</intervention_name>
    <description>FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg</description>
    <arm_group_label>fluticasone furoate/umeclidinium bromide/vilanterol</arm_group_label>
    <arm_group_label>fluticasone furoate/vilanterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vilanterol (VI)</intervention_name>
    <description>VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg</description>
    <arm_group_label>fluticasone furoate/umeclidinium bromide/vilanterol</arm_group_label>
    <arm_group_label>fluticasone furoate/vilanterol</arm_group_label>
    <arm_group_label>umeclidinium bromide/vilanterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>umeclidinium bromide (UMEC)</intervention_name>
    <description>UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg</description>
    <arm_group_label>fluticasone furoate/umeclidinium bromide/vilanterol</arm_group_label>
    <arm_group_label>umeclidinium bromide/vilanterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent: A signed and dated written informed consent prior to study
             participation

          -  Type of subject: Outpatient

          -  Age: Subjects 40 years of age or older at Visit 1

          -  Gender: Male or female subjects. A female is eligible to enter and participate in the
             study if she is of: Non-child bearing potential (i.e. physiologically incapable of
             becoming pregnant, including any female who is post-menopausal or surgically sterile).
             Surgically sterile females are defined as those with a documented hysterectomy and/or
             bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being
             amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age
             appropriate, &gt; 45 years, in the absence of hormone replacement therapy OR Child
             bearing potential, has a negative pregnancy test at screening, and agrees to one of
             the following acceptable contraceptive methods used consistently and correctly (i.e.
             in accordance with the approved product label and the instructions of the physician
             for the duration of the study - screening to safety follow-up contact): Abstinence;
             Oral Contraceptive, either combined or progestogen alone; Injectable progestogen;
             Implants of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive
             patches; Intrauterine device (IUD) or intrauterine system (IUS); Male partner
             sterilization (vasectomy with documentation of azoospermia) prior to the female
             subject's entry into the study, and this male is the sole partner for that subject.
             For this definition, &quot;documented&quot; refers to the outcome of the
             investigator's/designee's medical examination of the subject or review of the
             subject's medical history for study eligibility, as obtained via a verbal interview
             with the subject or from the subject's medical records. Double barrier method: condom
             and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal
             agent (foam/gel/film/cream/suppository)

          -  COPD Diagnosis: An established clinical history of COPD in accordance with the
             definition by the American Thoracic Society/European Respiratory Society

          -  Smoking History: Current or former cigarette smokers with a history of cigarette
             smoking of &gt;=10 pack-years at screening (visit 1) [number of pack years = (number of
             cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10
             years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those
             who have stopped smoking for at least 6 months prior to Visit 1. Note: Pipe and/or
             cigar use cannot be used to calculate pack-year history

          -  Severity of COPD symptoms: A score of &gt;=10 on the COPD Assessment Test (CAT) at
             screening

          -  Severity of COPD Disease: A post-albuterol/salbutamol FEV1/ Forced Vital Capacity
             (FVC) ratio of &lt;0.70 at Screening

          -  Existing COPD maintenance treatment: Subject must be receiving daily maintenance
             treatment for their COPD for at least 3 months prior to Screening. Note: Subjects
             receiving only Pro re nata (PRN) COPD medications are not eligible

          -  History of Exacerbations: Subjects must demonstrate: a post-bronchodilator FEV1 &lt;50%
             predicted normal and a documented history of &gt;= 1 moderate or severe COPD exacerbation
             in the previous 12 months OR a post-bronchodilator 50% &lt;=FEV1 &lt; 80% predicted normal
             and a documented history of &gt;= 2 moderate exacerbations or a documented history of &gt;=1
             severe COPD exacerbation (hospitalized) in the previous 12 months. Note: Percent
             predicted will be calculated using the European Respiratory Society Global Lung
             Function Initiative reference equations. Note: A documented history of a COPD
             exacerbation (e.g., medical record verification) is a medical record of worsening COPD
             symptoms that required systemic/oral corticosteroids and/or antibiotics (for a
             moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of
             antibiotics alone does not qualify as an exacerbation history unless the use was
             associated with treatment of worsening symptoms of COPD, such as increased dyspnea,
             sputum volume, or sputum purulence (color). Subject verbal reports are not acceptable

          -  Liver function tests: alanine aminotransferase (ALT) &lt;2x upper limit of normal (ULN);
             alkaline phosphatase &lt;=1.5xULN; bilirubin &lt;=1.5xULN (isolated bilirubin &gt;1.5 x ULN is
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%)

          -  French subjects: In France, a subject will be eligible for inclusion in this study
             only if either affiliated to or a beneficiary of a social security category

        Exclusion Criteria:

          -  Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant
             during the study

          -  Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of
             asthma are eligible if they have a current diagnosis of COPD)

          -  Alpha1-antitrypsin deficiency: Subjects with Alpha1-antitrypsin deficiency as the
             underlying cause of COPD

          -  Other respiratory disorders: Subjects with active tuberculosis, lung cancer,
             significant bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension,
             interstitial lung diseases or other active pulmonary diseases

          -  Lung resection: Subjects with lung volume reduction surgery within the 12 months prior
             to Screening

          -  Risk Factors for Pneumonia: immune suppression (e.g. human immunodeficiency virus
             [HIV], Lupus) or other risk factors for pneumonia (e.g. neurological disorders
             affecting control of the upper airway, such as Parkinson's Disease, Myasthenia
             Gravis). Patients at potentially high risk (e.g. very low BMI, severely malnourished,
             or very low FEV1) will only be included at the discretion of the Investigator

          -  Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least
             14 days prior to Screening and at least 30 days following the last dose of
             oral/systemic corticosteroids (if applicable). In addition, any subject that
             experiences pneumonia and/or moderate or severe COPD exacerbation during the run-in
             period will be excluded

          -  Other Respiratory tract infections that have not resolved at least 7 days prior to
             screening

          -  Abnormal Chest x-ray(CXR): Chest x-ray (posteroanterior and lateral) reveals evidence
             of pneumonia or a clinically significant abnormality not believed to be due to the
             presence of COPD, or another condition that would hinder the ability to detect an
             infiltrate on CXR (e.g. significant cardiomegaly, pleural effusion or scarring). All
             subjects will have a chest x-ray at Screening Visit 1 (or historical radiograph or
             computerised tomography (CT) scan obtained within 3 months prior to screening) that
             will be over-read by a central vendor. Note: Subjects who have experienced pneumonia
             and/or moderate or severe COPD exacerbation within 3 months of screening must provide
             a post pneumonia/exacerbation chest x-ray to be over-read by the central vendor or
             have a chest x-ray conducted at screening. For sites in Germany: If a chest x-ray (or
             CT scan) within 3 months prior to Screening (Visit 1) is not available, approval to
             conduct a diagnostic chest x-ray will need to be obtained from the Federal Office for
             Radiation Protection (Bundesamt f√ºr Strahlenschutz [BfS])

          -  Other diseases/abnormalities: Subjects with historical or current evidence of
             clinically significant cardiovascular, neurological, psychiatric, renal, hepatic,
             immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin,
             sensory, endocrine (including uncontrolled diabetes or thyroid disease) or
             hematological abnormalities that are uncontrolled. Significant is defined as any
             disease that, in the opinion of the Investigator, would put the safety of the subject
             at risk through participation, or which would affect the efficacy or safety analysis
             if the disease/condition exacerbated during the study

          -  Unstable liver disease as defined by the presence of ascites, encephalopathy,
             coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice,
             cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or
             asymptomatic gallstones).

          -  Note: Chronic stable hepatitis B and C are acceptable if the subject otherwise meets
             entry criteria

          -  Unstable or life threatening cardiac disease: subjects with any of the following at
             Screening (Visit 1) would be excluded: Myocardial infarction or unstable angina in the
             last 6 months; Unstable or life threatening cardiac arrhythmia requiring intervention
             in the last 3 months; New York Heart Association (NYHA) Class IV Heart failure

          -  Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding:
             Investigators will be provided with ECG reviews conducted by a centralized independent
             cardiologist to assist in evaluation of subject eligibility. The Principal
             Investigator will determine the clinical significance of each abnormal ECG finding in
             relation to the subject's medical history and exclude subjects who would be at undue
             risk by participating in the trial. An abnormal and clinically significant finding
             that would preclude a subject from entering the trial is defined as a 12-lead tracing
             that is interpreted as, but not limited to, any of the following: atrial fibrillation
             (AF) with rapid ventricular rate &gt;120 beats per minute); sustained or nonsustained
             ventricular tachycardia (VT); Second degree heart block Mobitz type II and third
             degree heart block (unless pacemaker or defibrillator had been inserted); QT interval
             corrected for heart rate (QTcF) &gt;=500 milliseconds (msec) in patients with QRS &lt;120
             msec and QTcF &gt;=530 msec in patients with QRS &gt;=120 msec

          -  Contraindications: A history of allergy or hypersensitivity to any corticosteroid,
             anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or
             magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic
             hypertrophy or bladder neck obstruction that, in the opinion of the Investigator
             contraindicates study participation

          -  Cancer: Subjects with carcinoma that has not been in complete remission for at least 5
             years. Subjects who have had carcinoma in situ of the cervix, squamous cell carcinoma
             and basal cell carcinoma of the skin would not be excluded based on the 5 year waiting
             period if the subject has been considered cured by treatment

          -  Oxygen therapy: Use of long-term oxygen therapy (LTOT) described as resting oxygen
             therapy &gt;3 Liter/minute (L/min) (Oxygen use =&lt;3L/min flow is not exclusionary)

          -  Medication prior to spirometry: Subjects who are medically unable to withhold their
             albuterol/salbutamol for the 4-hour period required prior to spirometry testing at
             each study visit

          -  Pulmonary rehabilitation: Subjects who have participated in the acute phase of a
             Pulmonary Rehabilitation Program within 4 weeks prior to Screening or subjects who
             plan to enter the acute phase of a Pulmonary Rehabilitation Program during the study.
             Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are
             not excluded

          -  Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug
             abuse within the last 2 years

          -  Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study
             procedures. Any infirmity, disability, or geographic location that would limit
             compliance for scheduled visits

          -  Questionable validity of consent: Subjects with a history of psychiatric disease,
             intellectual deficiency, poor motivation or other conditions that will limit the
             validity of informed consent to participate in the study

          -  Affiliation with investigator site: Study investigators, sub-investigators, study
             coordinators, employees of a participating investigator or study site, or immediate
             family members of the aforementioned that is involved with this study

          -  Inability to read: In the opinion of the Investigator, any subject who is unable to
             read and/or would not be able to complete study related materials

          -  Medication prior to screening: Use of the following medications within the following
             time intervals prior to Screening (Visit 1) or during the study: Long term antibiotic
             therapy Subjects receiving antibiotics for long term therapy are not eligible for the
             study (Antibiotics are allowed for the short term treatment of an exacerbation or for
             short term treatment of other acute infections during the study); Systemic, Oral,
             parenteral corticosteroids 30 days (Except during the study oral/systemic
             corticosteroids may be used to treat COPD exacerbations/pneumonia) Intra-articular
             injections are allowed; Any other investigational drug (30 days or 5 half lives
             whichever is longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Florence</city>
        <state>Alabama</state>
        <zip>35630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flagstaff</city>
        <state>Arizona</state>
        <zip>86001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reseda</city>
        <state>California</state>
        <zip>91335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Celebration</city>
        <state>Florida</state>
        <zip>34747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765-2616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponte Vedra Beach</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adairsville</city>
        <state>Georgia</state>
        <zip>30103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rincon</city>
        <state>Georgia</state>
        <zip>31326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gillespie</city>
        <state>Illinois</state>
        <zip>62033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quincy</city>
        <state>Illinois</state>
        <zip>62301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <zip>46131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muncie</city>
        <state>Indiana</state>
        <zip>47303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Mitchell</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Maryland</state>
        <zip>20636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <zip>01201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moorestown</city>
        <state>New Jersey</state>
        <zip>08057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronxville</city>
        <state>New York</state>
        <zip>10708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <zip>28467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <zip>27909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hendersonville</city>
        <state>North Carolina</state>
        <zip>28739</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>North Carolina</state>
        <zip>27292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shelby</city>
        <state>North Carolina</state>
        <zip>28152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tabor City</city>
        <state>North Carolina</state>
        <zip>28463</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Whiteville</city>
        <state>North Carolina</state>
        <zip>28472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <zip>19335</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <zip>19460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <zip>16684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406-7108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gonzales</city>
        <state>Texas</state>
        <zip>78629</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <zip>77339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sealy</city>
        <state>Texas</state>
        <zip>77474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bah√≠a Blanca</city>
        <state>Buenos Aires</state>
        <zip>B8000AAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1028AAP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Florida</city>
        <state>Buenos Aires</state>
        <zip>1602</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <zip>1900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nueve de Julio</city>
        <state>Buenos Aires</state>
        <zip>B6500BWQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paran√°</city>
        <state>Buenos Aires</state>
        <zip>E3100BHK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vicente Lopez</city>
        <state>Buenos Aires</state>
        <zip>B1602DOH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <state>C√≥rdova</state>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concepcion del Uruguay</city>
        <state>Entre R√≠os</state>
        <zip>3260</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Rafael</city>
        <state>Mendoza</state>
        <zip>5600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2002OJN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucum√°n</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berazategui, Buenos Aires</city>
        <zip>B1884AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berazategui</city>
        <zip>1886</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1424BSF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <zip>C1440BRR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenis Aires</city>
        <zip>C1015ABR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Aut√≥noma de Buenos Aires</city>
        <zip>C1121ABE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Aut√≥noma de Buenos Aires</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Aut√≥noma de Buenos Aires</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coronel Suarez</city>
        <zip>7540</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500CCG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monte Grande</city>
        <zip>1842</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salta</city>
        <zip>A4400ERH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel de Tucum√°n</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Rosa</city>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>2250</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daw Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Victoria</state>
        <zip>3300</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6964</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>2107</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Feldbach</city>
        <zip>8330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grieskirchen</city>
        <zip>A-4710</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thalheim bei Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erpent</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Li√®ge</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmedy</city>
        <zip>4960</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montigny-Le-Tilleul</city>
        <zip>6110</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roeselaere</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50920-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-074</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blumenau</city>
        <state>Santa Catarina</state>
        <zip>89030-101</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Florianopolis</city>
        <state>Santa Catarina</state>
        <zip>88040-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>S√£o Paulo</city>
        <zip>01323903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>S√£o Paulo</city>
        <zip>04023900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>S√£o Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>S√£o Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <zip>T8H 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cornwall</city>
        <state>Ontario</state>
        <zip>K6H4M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3A 1Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Charles-Borrom√©e</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concepci√≥n</city>
        <state>Regi√≥n Del Biobio</state>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curic√≥</city>
        <state>Regi√≥n Del Maule</state>
        <zip>3341643</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Talca</city>
        <state>Regi√≥n Del Maule</state>
        <zip>3465584</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puente Alto - Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>7750495</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>7860406</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>Regi√≥n Metro De Santiago</state>
        <zip>8360160</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Valpara√≠so</state>
        <zip>2341131</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vi√±a del Mar</city>
        <state>Valpara√≠so</state>
        <zip>2520024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500698</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Talcahuano</city>
        <zip>4270918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vi√±a del Mar</city>
        <zip>2520594</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266071</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fuzhou</city>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuxi</city>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogot√°</city>
        <zip>80CO</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bogot√°</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benesov</city>
        <zip>256 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cvikov</city>
        <zip>471 54</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holesov</city>
        <zip>769 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jaromer</city>
        <zip>551 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>772 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>70868</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <zip>182 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 19</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 10</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trebic</city>
        <zip>674 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolding</city>
        <zip>DK-6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>S√∏nderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02740</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lohja</city>
        <zip>08200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bayonne cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brest Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Briis-sous-Forge</city>
        <zip>91640</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille cedex 03</city>
        <zip>13331</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montauban cedex</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nimes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orl√©ans cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pringy cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Strasbourg cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leonberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>71229</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70372</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70378</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <state>Bayern</state>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Woerrishofen</city>
        <state>Bayern</state>
        <zip>86825</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bamberg</city>
        <state>Bayern</state>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dachau</city>
        <state>Bayern</state>
        <zip>85221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dillingen</city>
        <state>Bayern</state>
        <zip>89407</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Donaustauf</city>
        <state>Bayern</state>
        <zip>93093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garmisch-Partenirchen</city>
        <state>Bayern</state>
        <zip>82467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gauting</city>
        <state>Bayern</state>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Landsberg</city>
        <state>Bayern</state>
        <zip>86899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nuernberg</city>
        <state>Bayern</state>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosenheim</city>
        <state>Bayern</state>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wallerfing</city>
        <state>Bayern</state>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cottbus</city>
        <state>Brandenburg</state>
        <zip>03050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rathenow</city>
        <state>Brandenburg</state>
        <zip>14712</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruedersdorf</city>
        <state>Brandenburg</state>
        <zip>15562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bensheim</city>
        <state>Hessen</state>
        <zip>64625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankenberg</city>
        <state>Hessen</state>
        <zip>35066</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fuldatal</city>
        <state>Hessen</state>
        <zip>34233</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neu isenburg</city>
        <state>Hessen</state>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rodgau</city>
        <state>Hessen</state>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruesselsheim</city>
        <state>Hessen</state>
        <zip>65428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peine</city>
        <state>Niedersachsen</state>
        <zip>31224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wardenburg</city>
        <state>Niedersachsen</state>
        <zip>26203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Lippspringe</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33175</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergisch Gladbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dueren</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52349</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freudenberg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>57258</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gelsenkirchen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45879</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gummersbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51643</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kleve</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ratingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40878</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rheine</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Solingen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warendorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bernkastel-Kues</city>
        <state>Rheinland-Pfalz</state>
        <zip>54470</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neuwied</city>
        <state>Rheinland-Pfalz</state>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wissen</city>
        <state>Rheinland-Pfalz</state>
        <zip>57537</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saarbruecken</city>
        <state>Saarland</state>
        <zip>66111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halberstadt</city>
        <state>Sachsen-Anhalt</state>
        <zip>38820</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hettstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>06333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Teuchern</city>
        <state>Sachsen-Anhalt</state>
        <zip>06682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zerbst</city>
        <state>Sachsen-Anhalt</state>
        <zip>39261</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auerbach</city>
        <state>Sachsen</state>
        <zip>08209</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delitzsch</city>
        <state>Sachsen</state>
        <zip>04509</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzg</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geesthacht</city>
        <state>Schleswig-Holstein</state>
        <zip>21502</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23558</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reinfeld</city>
        <state>Schleswig-Holstein</state>
        <zip>23858</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schleswig</city>
        <state>Schleswig-Holstein</state>
        <zip>24837</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gera</city>
        <state>Thueringen</state>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saalfeld</city>
        <state>Thueringen</state>
        <zip>07318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmoelln</city>
        <state>Thueringen</state>
        <zip>04626</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10961</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggendorf</city>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22291</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kwun Tong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lai Chi Kok</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuen Mun</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>67891</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>455-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>457-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>471-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>485-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>278-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>296-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ehime</city>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>802-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>816-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>506-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>509-6134</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>372-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gunma</city>
        <zip>373-0807</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>722-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>735-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>001-0901</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>053-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>062-8618</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>064-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>064-0915</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>071-8132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>078-8211</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>080-0805</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>651-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>653-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>664-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>670-0849</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>674-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>675-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>302-0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>310-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>311-3193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>317-0077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ibaraki</city>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ishikawa</city>
        <zip>920-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ishikawa</city>
        <zip>921-8105</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ishikawa</city>
        <zip>923-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iwate</city>
        <zip>020-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>760-0018</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>760-8538</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>761-8073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>762-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>210-0852</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>239-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>252-5188</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>254-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kochi</city>
        <zip>780-8077</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-1196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>601-1495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8087</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mie</city>
        <zip>510-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mie</city>
        <zip>515-8544</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>984-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>985-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>986-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>989-1253</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagano</city>
        <zip>392-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Niigata</city>
        <zip>940-0856</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oita</city>
        <zip>870-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>701-0304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>702-8055</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>711-0921</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>901-2121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>901-2132</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>901-2393</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>904-2143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>904-2293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>533-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>559-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>564-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>576-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>576-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>591-8037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saitama</city>
        <zip>349-1105</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shizuoka</city>
        <zip>430-8525</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tochigi</city>
        <zip>320-0065</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>120-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>134-0083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>158-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>194-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>198-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>204-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toyama</city>
        <zip>937-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toyama</city>
        <zip>938-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wakayama</city>
        <zip>640-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yamagata</city>
        <zip>990-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yamanashi</city>
        <zip>400-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yamanashi</city>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon city, Gyenggi-do</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cheongju-si, Chungcheongbuk-do</city>
        <zip>361-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>431-796</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>403-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-791</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>134-814</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7606 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Assen</city>
        <zip>9401 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Den Bosch</city>
        <zip>5223 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dordrecht</city>
        <zip>3318 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844 DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kloosterhaar</city>
        <zip>7694 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3083 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spijkenisse</city>
        <zip>3207 NB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auckland</city>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <zip>9012</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newtown, Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bod√∏</city>
        <zip>8005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1606</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hakadal</city>
        <zip>1487</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kl√∏fta</city>
        <zip>2040</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Levanger</city>
        <zip>7600</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0953</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4005</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>7027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pueblo Libre</city>
        <state>Lima</state>
        <zip>Lima 21</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <zip>Lima 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <zip>Lima 32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>L 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>L41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 14</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>Lima 41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caloocan City</city>
        <zip>1400</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iloilo</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jaro, Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pasig</city>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-741</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarn√≥w</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zgierz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guaynabo</city>
        <zip>00968</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mayaguez</city>
        <zip>00680</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Braila</city>
        <zip>810003</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Comuna Alexandru Cel Bun</city>
        <zip>617507</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <zip>100184</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ploiesti</city>
        <zip>100379</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ramnicu Valcea</city>
        <zip>240564</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belgorod</city>
        <zip>308007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blagoveshchensk</city>
        <zip>675000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chita</city>
        <zip>672000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chita</city>
        <zip>672090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kazan</city>
        <zip>420015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novgorod</city>
        <zip>173008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198216</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulan-Ude</city>
        <zip>670031</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vladivostok</city>
        <zip>690002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vladivostok</city>
        <zip>690950</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Volgodonsk</city>
        <zip>347381</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vsevolozhsk, Leningrad Region</city>
        <zip>188640</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>117599</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169856</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>609606</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benoni</city>
        <state>Gauteng</state>
        <zip>1501</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boksburg</city>
        <state>Gauteng</state>
        <zip>1459</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0183</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Val De Grace, Pretoria</city>
        <state>Gauteng</state>
        <zip>0184</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Middelburg</city>
        <state>Mpumalanga</state>
        <zip>1055</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amanzimtoti</city>
        <zip>4126</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellville</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boksburg North</city>
        <zip>1459</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7129</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7572</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>CapeTown</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatesville</city>
        <zip>7764</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2113</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Korsten</city>
        <zip>6014</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mowbray</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paarl</city>
        <zip>7646</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panorama</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tygerberg</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marbella - M√°laga</city>
        <state>Andalucia</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laredo</city>
        <state>Cantabria</state>
        <zip>39770</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrelavega</city>
        <state>Cantabria</state>
        <zip>39300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalonia</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>(Badalona) Barcelona</city>
        <zip>08911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>(Barakaldo) Vizcaya</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alzira/Valencia</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basurto/Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centelles (Barcelona)</city>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coslada</city>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>C√°ceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gerona</city>
        <zip>17005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Coru√±a</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Coru√±a</city>
        <zip>15011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Roca Del Valles (Barcelona)</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Matar√≥</city>
        <zip>08303</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>M√°laga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>M√©rida (Badajoz)</city>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peralada( Girona)</city>
        <zip>17491</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Petrer/Alicante</city>
        <zip>03610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponferrada (Le√≥n)</city>
        <zip>24411</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pozuelo De Alarc√≥n/Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sagunto/Valencia</city>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan De Alicante</city>
        <zip>3550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarragona</city>
        <zip>43002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vizcaya</city>
        <zip>48902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bor√•s</city>
        <zip>SE-506 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>G√∂teborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>G√∂teborg</city>
        <zip>SE-413 90</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>H√∂llviken</city>
        <zip>SE-236 32</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Link√∂ping</city>
        <zip>SE-587 58</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lule√•</city>
        <zip>SE-971 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-752 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>√ñrebro</city>
        <zip>SE-703 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>√ñstersund</city>
        <zip>SE-831 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10600</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiangmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muang</city>
        <zip>11000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nan</city>
        <zip>55000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34020</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34844</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mykolayiv</city>
        <zip>54003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wishaw</city>
        <state>Lanarkshire</state>
        <zip>ML2 0DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>High Heaton, Newcastle Upon Tyne</city>
        <state>Tyne &amp; Wear</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <state>Wiltshire</state>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baillieston, Glasgow</city>
        <zip>G69 7AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chester</city>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crawley</city>
        <zip>RH10 7DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crownhill, Plymouth</city>
        <zip>PL5 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dundee, Scotland</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sidcup, Kent</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <zip>BA14 9AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ha Noi</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <results_first_submitted>July 6, 2018</results_first_submitted>
  <results_first_submitted_qc>September 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2018</results_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>umeclidinium</keyword>
  <keyword>fluticasone furoate</keyword>
  <keyword>vilanterol</keyword>
  <keyword>triple therapy</keyword>
  <keyword>exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02164513/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02164513/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with chronic obstructive pulmonary disease (COPD), were randomized to the study. Study was conducted from 30 June 2014 to 17 July 2017, at total of 971 sites in 37 countries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FF/UMEC/VI</title>
          <description>The eligible participants in this arm received Fluticasone Furoate (FF)/Umeclidinium (UMEC)/Vilanterol (VI) as a fixed dose combination (FDC) as 100 microgram (¬µcg)/62.5¬µcg/25¬µcg once daily (QD) via a dry powder inhaler (DPI), in the morning, for duration of 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>FF/VI</title>
          <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>UMEC/VI</title>
          <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4151"/>
                <participants group_id="P2" count="4134"/>
                <participants group_id="P3" count="2070"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Investigational Product (IP)</title>
              <participants_list>
                <participants group_id="P1" count="3393"/>
                <participants group_id="P2" count="3094"/>
                <participants group_id="P3" count="1504"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Not Completed IP</title>
              <participants_list>
                <participants group_id="P1" count="758"/>
                <participants group_id="P2" count="1040"/>
                <participants group_id="P3" count="566"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP (WIP): Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="325"/>
                <participants group_id="P3" count="186"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP: Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="313"/>
                <participants group_id="P3" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew IP: Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP (Other): Stopping Criteria Reached</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP: Study Closed/Terminated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP: Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP: Investigator Discretion</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP: Withdrawal by Participant</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>WIP :Did Not Complete Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3714"/>
                <participants group_id="P2" count="3598"/>
                <participants group_id="P3" count="1775"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
                <participants group_id="P2" count="536"/>
                <participants group_id="P3" count="295"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Study Closed or terminated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="192"/>
                <participants group_id="P2" count="261"/>
                <participants group_id="P3" count="130"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other: Reason not provided by site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FF/UMEC/VI</title>
          <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>FF/VI</title>
          <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>UMEC/VI</title>
          <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4151"/>
            <count group_id="B2" value="4134"/>
            <count group_id="B3" value="2070"/>
            <count group_id="B4" value="10355"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="8.24"/>
                    <measurement group_id="B2" value="65.3" spread="8.30"/>
                    <measurement group_id="B3" value="65.2" spread="8.26"/>
                    <measurement group_id="B4" value="65.3" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1385"/>
                    <measurement group_id="B2" value="1386"/>
                    <measurement group_id="B3" value="714"/>
                    <measurement group_id="B4" value="3485"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2766"/>
                    <measurement group_id="B2" value="2748"/>
                    <measurement group_id="B3" value="1356"/>
                    <measurement group_id="B4" value="6870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="374"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3200"/>
                    <measurement group_id="B2" value="3179"/>
                    <measurement group_id="B3" value="1604"/>
                    <measurement group_id="B4" value="7983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI</title>
        <description>The annual rate of moderate or severe COPD exacerbations which occurred during treatment was assessed. Moderate exacerbations were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Analysis performed using a generalized linear model assuming a negative binomial distribution. ITT population was used which comprised of all randomized participants, excluding those who were randomized in error. Only those participants with non-missing co-variates were included in the analysis.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI</title>
            <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UMEC/VI</title>
            <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI</title>
          <description>The annual rate of moderate or severe COPD exacerbations which occurred during treatment was assessed. Moderate exacerbations were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Analysis performed using a generalized linear model assuming a negative binomial distribution. ITT population was used which comprised of all randomized participants, excluding those who were randomized in error. Only those participants with non-missing co-variates were included in the analysis.</description>
          <population>ITT Population.</population>
          <units>Exacerbations per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4145"/>
                <count group_id="O2" value="4133"/>
                <count group_id="O3" value="2069"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="0.87" upper_limit="0.95"/>
                    <measurement group_id="O2" value="1.07" lower_limit="1.02" upper_limit="1.12"/>
                    <measurement group_id="O3" value="1.21" lower_limit="1.14" upper_limit="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-values should be compared against a reference level of 0.05 in order to infer statistical significance for either of the comparisons.</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
            <estimate_desc>Covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted Forced expiratory volume in 1 second (FEV1) (Screening) were used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-values should be compared against a reference level of 0.05 in order to infer statistical significance for either of the comparisons</p_value_desc>
            <method>Negative binomial model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>Covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted Forced expiratory volume in 1 second (FEV1) (Screening) were used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI</title>
        <description>FEV1 was defined as the amount of air a person exhales in one second. Change from Baseline was calculated as the value of FEV1 at Week 52 minus the value at Baseline. Baseline for trough FEV1 was defined as Day 1 (Pre-dose). Only those participants with non-missing co-variates were included in the analysis. The analysis was performed using a Repeated measures model with covariates of treatment group, smoking status (Screening), geographical region, visit, Baseline, Baseline by visit and treatment group by visit interactions.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI</title>
            <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1), at Week 52 Comparing FF/UMEC/VI With FF/VI</title>
          <description>FEV1 was defined as the amount of air a person exhales in one second. Change from Baseline was calculated as the value of FEV1 at Week 52 minus the value at Baseline. Baseline for trough FEV1 was defined as Day 1 (Pre-dose). Only those participants with non-missing co-variates were included in the analysis. The analysis was performed using a Repeated measures model with covariates of treatment group, smoking status (Screening), geographical region, visit, Baseline, Baseline by visit and treatment group by visit interactions.</description>
          <population>ITT Population.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3366"/>
                <count group_id="O2" value="3060"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.094" spread="0.0042"/>
                    <measurement group_id="O2" value="-0.003" spread="0.0044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value at Week 52 should be compared against a reference level of 0.05 in order to infer statistical significance for the comparison of FF/UMEC/VI versus (vs) FF/VI at Week 52.</p_value_desc>
            <method>Mixed Models Repeated Measures</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.097</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI</title>
        <description>SGRQ is a disease specific-questionnaire, designed to measure impact of respiratory disease and its treatment on a COPD participant's Health Related Quality of Life (HRQoL). SGRQ contains 14 questions with total of 40 items grouped into three domains (Symptoms, Activity, and Impacts). The overall summary score along with scores for the individual domains of symptoms, activity and impacts were assessed. Score was calculated by summing the pre-assigned weights of answers, dividing by sum of maximum weights for items in SGRQ. Total scores ranged from 0 to 100. A decrease in score indicates improvement in HRQoL and higher score implies worse quality of life. Change from Baseline was calculated as total score at Week 52 minus value at Baseline. Baseline was defined as Day 1. Minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Only those participants with non-missing co-variates were included in the analysis.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI</title>
            <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in St. George's Respiratory Questionnaire for (SGRQ) Total Score at Week 52 Comparing FF/UMEC/VI With FF/VI</title>
          <description>SGRQ is a disease specific-questionnaire, designed to measure impact of respiratory disease and its treatment on a COPD participant's Health Related Quality of Life (HRQoL). SGRQ contains 14 questions with total of 40 items grouped into three domains (Symptoms, Activity, and Impacts). The overall summary score along with scores for the individual domains of symptoms, activity and impacts were assessed. Score was calculated by summing the pre-assigned weights of answers, dividing by sum of maximum weights for items in SGRQ. Total scores ranged from 0 to 100. A decrease in score indicates improvement in HRQoL and higher score implies worse quality of life. Change from Baseline was calculated as total score at Week 52 minus value at Baseline. Baseline was defined as Day 1. Minimum clinically important difference (MCID) for this instrument is a 4-point improvement (decrease from Baseline). Only those participants with non-missing co-variates were included in the analysis.</description>
          <population>ITT Population.</population>
          <units>Scores on SGRQ scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3318"/>
                <count group_id="O2" value="3026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="0.23"/>
                    <measurement group_id="O2" value="-3.7" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-value at Week 52 should be compared against a reference level of 0.05 in order to infer statistical significance for the comparison of FF/UMEC/VI vs FF/VI at Week 52.</p_value_desc>
            <method>Mixed Models Repeated Measures</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI</title>
        <description>This measures the number of days, to the first onset of moderate or severe exacerbations. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. The Hazard ratio from Cox proportional hazards model with covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening), have been reported. Only those participants with non-missing co-variates were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI</title>
            <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UMEC/VI</title>
            <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With FF/VI and With UMEC/VI</title>
          <description>This measures the number of days, to the first onset of moderate or severe exacerbations. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. The Hazard ratio from Cox proportional hazards model with covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening), have been reported. Only those participants with non-missing co-variates were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</description>
          <population>ITT Population.</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1959"/>
                <count group_id="O2" value="2039"/>
                <count group_id="O3" value="1036"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First quartile time to onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median time to onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</measurement>
                    <measurement group_id="O2" value="NA">If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</measurement>
                    <measurement group_id="O3" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The adjusted p-values should be compared against a reference level of 0.05 in order to infer statistical significance for either of the comparisons.</p_value_desc>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count &gt;=150 Cells Per Microliter</title>
        <description>The annual rate of moderate or severe COPD exacerbations during the treatment, for participants with blood eosinophil count &gt;=150 cells per microliter , has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non-missing eosinophil, at Baseline were included in the analysis.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UMEC/VI</title>
            <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI in the Subset of Participants With a Blood Eosinophil Count &gt;=150 Cells Per Microliter</title>
          <description>The annual rate of moderate or severe COPD exacerbations during the treatment, for participants with blood eosinophil count &gt;=150 cells per microliter , has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non-missing eosinophil, at Baseline were included in the analysis.</description>
          <population>ITT Population</population>
          <units>Exacerbations per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2296"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.90" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.39" lower_limit="1.29" upper_limit="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial Model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count &gt;=150 Cells Per Microliter at Baseline</title>
        <description>This measures the number of days, to the first onset of moderate or severe exacerbations for participants with blood eosinophil count &gt;=150 cells per microliter, at Baseline has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non missing eosinophils at Baseline were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>UMEC/VI</title>
            <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First On-treatment Moderate/Severe Exacerbation Comparing FF/UMEC/VI With UMEC/VI in the Subset of Particpants With a Blood Eosinophil Count &gt;=150 Cells Per Microliter at Baseline</title>
          <description>This measures the number of days, to the first onset of moderate or severe exacerbations for participants with blood eosinophil count &gt;=150 cells per microliter, at Baseline has been reported. Moderate exacerbations, were defined as exacerbations that required treatment with oral/systemic corticosteroids and/or antibiotics (not involving hospitalization or resulting in death). Severe exacerbations, were defined as exacerbations that required hospitalization or resulted in death. Only those participants with non-missing co-variates and non missing eosinophils at Baseline were included in the analysis. First quartile and median time to onset are taken from the Kaplan-Meier estimates. If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</description>
          <population>ITT Population</population>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2296"/>
                <count group_id="O2" value="1195"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First quartile time to onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Median time to onset</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">If &lt;25% (and &lt;50%) of participants experienced the event within a treatment then Q1 (and median) time to onset are displayed as NA (not applicable) for that treatment.</measurement>
                    <measurement group_id="O2" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazard model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI</title>
        <description>The annual rate of severe COPD exacerbations during the treatment, has been reported. Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. The covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening) were used. Only those participants with non-missing co-variates were included in the analysis</description>
        <time_frame>Up to Week 52</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>FF/UMEC/VI</title>
            <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>FF/VI</title>
            <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>UMEC/VI</title>
            <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of On-treatment Severe Exacerbations Comparing FF/UMEC/VI With FF/VI and With UMEC/VI</title>
          <description>The annual rate of severe COPD exacerbations during the treatment, has been reported. Severe exacerbations were defined as exacerbations that required hospitalization or resulted in death. The covariates of treatment group, sex, exacerbation history (&lt;=1, &gt;=2 moderate/severe), smoking status (Screening), geographical region and post-bronchodilator percent predicted FEV1 (Screening) were used. Only those participants with non-missing co-variates were included in the analysis</description>
          <population>ITT Population.</population>
          <units>Exacerbations per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4145"/>
                <count group_id="O2" value="4133"/>
                <count group_id="O3" value="2069"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.12" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.13" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.19" lower_limit="0.17" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.064</p_value>
            <method>Negative binomial model</method>
            <param_type>Rate Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial model</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>On-treatment Serious adverse events (SAEs) and Adverse events (AEs) are reported from the first dose of randomized medication up to Week 52.</time_frame>
      <desc>All AEs and SAEs in the ITT Population were reported. The number of on-treatment deaths are reported from date of first dose of study medication up to the day after the last date of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>FF/UMEC/VI 100/62.5/25</title>
          <description>The eligible participants in this arm received FF/UMEC/VI as a FDC as 100 ¬µcg/62.5¬µcg/25¬µcg, QD via a DPI, in the morning, for duration of 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>FF/VI 100/25</title>
          <description>The eligible participants in this arm received FF/VI 100¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>UMEC/VI 62.5/25</title>
          <description>The eligible participants in this arm received UMEC/VI 62.5¬µcg/25¬µcg QD via DPI, in the morning for duration of 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="4151"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="4134"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="895" subjects_at_risk="4151"/>
                <counts group_id="E2" subjects_affected="850" subjects_at_risk="4134"/>
                <counts group_id="E3" subjects_affected="470" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemorrhagic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="4151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4134"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4151"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="4151"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4134"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atrioventricular dissociation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="4151"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="28" subjects_affected="21" subjects_at_risk="4151"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4134"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cor pulmonale chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4151"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4134"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Myocardial bridging</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Odontogenic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pancreatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peritoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Retroperitoneal fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Implant site fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Medical device site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4151"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4151"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infected varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4151"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="4134"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4151"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4134"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="198" subjects_affected="184" subjects_at_risk="4151"/>
                <counts group_id="E2" events="165" subjects_affected="152" subjects_at_risk="4134"/>
                <counts group_id="E3" events="55" subjects_affected="54" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4151"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4134"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Subacute endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4134"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chemical peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Conjunctival laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Post procedural stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy prostate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Streptococcus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acetonaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bone infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Femoroacetabular impingement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4151"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spinal deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Benign fallopian tube neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Colon cancer stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Epiglottic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Glottis carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemangioma of spleen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatic angiosarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4151"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of unknown primary site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Monoclonal gammopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour of the lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Oral neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Soft tissue sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Urethral cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Brain stem ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Brain stem stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebral amyloid angiopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4151"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral nerve paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Simple partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Psychotic disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4151"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4134"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bladder disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bladder stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Renal aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Vesicocutaneous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="4151"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="4134"/>
                <counts group_id="E3" events="20" subjects_affected="16" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Asthma-chronic obstructive pulmonary disease overlap syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="554" subjects_affected="443" subjects_at_risk="4151"/>
                <counts group_id="E2" events="569" subjects_affected="450" subjects_at_risk="4134"/>
                <counts group_id="E3" events="337" subjects_affected="269" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="4151"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="4134"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="4151"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4151"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4134"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary hilum mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="4151"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="4134"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Neuropathic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peau d'orange</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute aortic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4151"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Varicose ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4151"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4134"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1389" subjects_at_risk="4151"/>
                <counts group_id="E2" subjects_affected="1278" subjects_at_risk="4134"/>
                <counts group_id="E3" subjects_affected="596" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="712" subjects_affected="520" subjects_at_risk="4151"/>
                <counts group_id="E2" events="658" subjects_affected="479" subjects_at_risk="4134"/>
                <counts group_id="E3" events="316" subjects_affected="222" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="401" subjects_affected="297" subjects_at_risk="4151"/>
                <counts group_id="E2" events="383" subjects_affected="283" subjects_at_risk="4134"/>
                <counts group_id="E3" events="162" subjects_affected="117" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="203" subjects_affected="161" subjects_at_risk="4151"/>
                <counts group_id="E2" events="176" subjects_affected="146" subjects_at_risk="4134"/>
                <counts group_id="E3" events="50" subjects_affected="41" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="165" subjects_affected="142" subjects_at_risk="4151"/>
                <counts group_id="E2" events="152" subjects_affected="120" subjects_at_risk="4134"/>
                <counts group_id="E3" events="83" subjects_affected="70" subjects_at_risk="2070"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="131" subjects_affected="121" subjects_at_risk="4151"/>
                <counts group_id="E2" events="135" subjects_affected="127" subjects_at_risk="4134"/>
                <counts group_id="E3" events="43" subjects_affected="41" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="180" subjects_affected="146" subjects_at_risk="4151"/>
                <counts group_id="E2" events="164" subjects_affected="139" subjects_at_risk="4134"/>
                <counts group_id="E3" events="101" subjects_affected="83" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="385" subjects_affected="233" subjects_at_risk="4151"/>
                <counts group_id="E2" events="332" subjects_affected="197" subjects_at_risk="4134"/>
                <counts group_id="E3" events="139" subjects_affected="101" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="168" subjects_affected="145" subjects_at_risk="4151"/>
                <counts group_id="E2" events="128" subjects_affected="117" subjects_at_risk="4134"/>
                <counts group_id="E3" events="75" subjects_affected="58" subjects_at_risk="2070"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

